Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYLINE 102: VX-121 Combination Therapy in Cystic Fibrosis (F/MF)
NCT05033080Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of vanzacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Sep 2021; status: completed.
02
Drugs
vanzacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05033080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033080.